News

Filter

Resubmission expected for Orexigen's obesity drug Contrave

29-08-2013

US biopharma company Orexigen Therapeutics (Nasdaq: OREX) has announced that the Light Study independent…

Arena PharmaceuticalsBelviqContraveGastro-intestinalsNorth AmericaOrexigen TherapeuticsPharmaceuticalQnexaRegulationVivus

Focus on weight-loss drugs in Latin America

23-07-2013

The increasing prevalence of obesity in Brazil and Mexico is encouraging its governments to consider…

Abbott LaboratoriesArena PharmaceuticalsBelviqByettaGastro-intestinalsHealthcareJohnson & JohnsonNovo NordiskPharmaceuticalQsymiaReductilRocheSouth AmericaTopamaxVictozaVivusXenical

It's official: "obesity is a disease," says AMA

20-06-2013

The American Medical Association at its annual meeting this week adopted a policy that recognizes obesity…

Arena PharmaceuticalsBelviqEisaiMarkets & MarketingMetabolicsNorth AmericaPharmaceuticalQsymiaRegulationVivus

Vivus' Qsymia set to be most widely used emerging therapy for obesity treatment

26-07-2012

Novel emerging agents will experience rapid uptake owing to the high prevalence of obese or overweight…

Arena PharmaceuticalsBelviqMarkets & MarketingMetabolicsPharmaceuticalQsymiaVivus

FDA updates on obesity drug candidates

11-01-2012

There have been two pieces of positive news coming out of the US Food and Drug Administration this week…

Arena PharmaceuticalsEisailorcaserinLorquessMetabolicsNorth AmericaPharmaceuticalQnexaRegulationVivus

Obesity drug market set to grow to $2.6 billion by 2020, says DR report

27-09-2011

The obesity drug market will increase more than six-fold over the next decade, increasing from $420 million…

Arena PharmaceuticalsContraveLorqessMarkets & MarketingMetabolicsNovo NordiskOrexigen TherapeuticsPharmaceuticalQnexaVictozaVivus

Vivus plummets 62% as FDA advisory meeting rejects approval of its obesity drug Qnexa

16-07-2010

In a fairly unexpected decision, a US Food and Drug Administration advisory panel yesterday voted 10…

Arena PharmaceuticalsContravelorcaserinMetabolicsNorth AmericaOrexigen TherapeuticsPharmaceuticalQnexaRegulationVivus

COMPANY SPOTLIGHT

Menarini

Back to top